Acta Med. 2011, 54: 51-57
https://doi.org/10.14712/18059694.2016.18
B Cell Toll-like Receptors with Respect to the Pathogenesis of Sjögren’s Syndrome
References
1. L, Holt AC, Medzhitov R, Flavell RA. Recognition of doublestranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 2001 Oct 18;413(6857):732–8.
<https://doi.org/10.1038/35099560>
2. ZK, Krieg AM, Warren T et al. Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs. J Immunol 2001; 67(9):4878–86.
<https://doi.org/10.4049/jimmunol.167.9.4878>
3. NL, Onai N, Lanzavecchia A. A role for Toll-like receptors in acquired immunity: up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells. Blood. 2003 Jun 1;101(11):4500–4.
<https://doi.org/10.1182/blood-2002-11-3569>
4. E, Bosisio D, Golay J, Polentarutti N, Mantovani A. The toll-like receptor repertoire of human B lymphocytes: inducible and selective expression of TLR9 and TLR10 in normal and transformed cells. Blood 2003 Aug 1;102(3): 956–63.
<https://doi.org/10.1182/blood-2002-11-3355>
5. MW, Broughton C, Mackay F, Akira S, Marshak-Rothstein A, Rifkin IR. Toll-like receptor 9-dependent and -independent dendritic cell activation by chromatin- immunoglobulin G complexes. J. Exp. Med. 2004 June 21; 199(12): 1631–1640.
<https://doi.org/10.1084/jem.20031942>
<PubMed>
6. Carsons S, Harris EK et al. The new Sjogren’s syndrome handbook. 1998; 3–10,71–85.
7. SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science. 2004 Mar 5;303(5663):1529–31.
<https://doi.org/10.1126/science.1093616>
8. M, Niino M, Adatia F, et al. Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. J Immunol 2007;178:6092–6099.
<https://doi.org/10.4049/jimmunol.178.10.6092>
9. RI, Pearson G, Vaughan JH. Detection of Epstein-Barr virus-associated antigens and DNA in salivary gland biopsies from patients with Sjőgren’s syndrome. J Immunol 1986;137:3162–8.
10. B, Tsan MF. Endotoxin contamination in recombinant human heat shock protein 70 (Hsp70) preparation is responsible for the induction of tumor necrosis factor a release by murine macrophages. J. Biol. Chem 2003;278:174.
<https://doi.org/10.1074/jbc.M208742200>
11. KB, Gorski KS, Gibson SJ, et al. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J Immunol. 2005;174: 1259–1268.
<https://doi.org/10.4049/jimmunol.174.3.1259>
12. JA, Vasilakos JP, Riter CL, Neys L, Lipson KE, Alkan SS, Birmachu W. Comparison of human B cell activation by TLR7 and TLR9 agonists. BMC Immunol 2008;9:39.
<https://doi.org/10.1186/1471-2172-9-39>
<PubMed>
13. F, Hemmi H, Hochrein H, et. al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science. 2004 Mar 5;303(5663):1526–9.
<https://doi.org/10.1126/science.1093620>
14. H, Kaisho T, Takeuchi O, et. al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol. 2002 Feb;3(2):196–200.
<https://doi.org/10.1038/ni758>
15. Horng T, Barton GM, Medzhitov R. TIRAP: an adapter molecule in the Toll signaling pathway. Nat Immunol 2001 Sep;2(9
16. D, Dřízhal I, Erbenová E, et al. HL-A in Sjögren’s syndrome. Tissue Antigens. 1976 Jan;7(1):45–51.
<https://doi.org/10.1111/j.1399-0039.1976.tb01028.x>
17. Z, Mak TW, Sen G, Li X. Toll-like receptor 3-mediated activation of NFkappaB and IRF3 diverges at Toll-IL-1 receptor domain-containing adapter inducing IFN-beta. Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3533–8.
<https://doi.org/10.1073/pnas.0308496101>
<PubMed>
18. Jonsson R, Bowman S, Gordon T. Sjőgren‘s syndrome. In: Koopman W, Moreland L, eds. Arthritis and Allied Conditions – A Text- book of Rheumatology. Philadelphia, USA: Lippincott Williams and Wilkins, 2005:1681–705.
19. R, Bolstad AI, Brokstad KA, Brun JG. Sjögren’s syndrome—a plethora of clinical and immunological phenotypes with a complex genetic background. Ann N Y Acad Sci. 2007 Jun;1108:433–47.
<https://doi.org/10.1196/annals.1422.046>
20. P, Dřízhal I, Živný P. Orální lichen planus a hepatitida C. LKS č.2. 2006 Feb;16:18–21.
21. T, Adachi O, Ogawa T, Takeda K, Akira S. Unresponsiveness of MyD88- deficient mice to endotoxin. Imunity 1999 Jul;11(1):115–22.
<https://doi.org/10.1016/S1074-7613(00)80086-2>
22. T, Takeuchi O, Fujita T, et al. Lipopolysaccharide stimulates the MyD88- independent pathway and results in activation of IRF-3 and the expression of a subset of LPS-inducible genes. J. Immunol 2001 Nov 15;167(10):5887–94.
<https://doi.org/10.4049/jimmunol.167.10.5887>
23. A, Nakashima K, Tamai M, et al. Toll-like receptor in salivary glands from patients with Sjögren’s syndrome: functional analysis by human salivary gland cell line. J Rheumatol. 2007 May;34(5):1019–26.
24. WU, Sreih A, Bucala R. Toll-like receptors in systemic lupus erythematosus; prospects for therapeutic intervention. Autoimmun Rev. 2009 Jan;8(3):204–8.
<https://doi.org/10.1016/j.autrev.2008.07.046>
<PubMed>
25. A, Rothenfusser S, Hornung V, et al. Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. Eur J Immunol 2001;31(7):2154–63.
<https://doi.org/10.1002/1521-4141(200107)31:7<2154::AID-IMMU2154>3.0.CO;2-U>
26. A, Sallusto F. Toll-like receptors and innate immunity in B-cell activation and antibody responses. Curr Opin Immunol. 2007 Jun;19(3):268–74.
<https://doi.org/10.1016/j.coi.2007.04.002>
27. CM, Broughton C, Tabor AS, Akira S, Flavell RA et al: RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. J Exp Med 2005. 202: 1171–7.
<https://doi.org/10.1084/jem.20050630>
<PubMed>
28. A, Rifkin IR, Hohlbaum AM Beaudette BC, Shlomchik MJ, Marshak- Rothstein A: Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 2002 416: 603–7.
<https://doi.org/10.1038/416603a>
29. FE. Cytokine-producing B lymphocytes – key regulators of immunity. Curr Opin Immunol 2008 June, 20(3):332–338.
<https://doi.org/10.1016/j.coi.2008.03.003>
<PubMed>
30. C, Heidemann J, von Eiff C. Human intestinal microvascular endothelial cells express Toll-like receptor 5: a binding partner for bacterial flagellin. J. Immunol 2004;172:5056.
<https://doi.org/10.4049/jimmunol.172.8.5056>
31. S, Pulendran B. Modulation of adaptive immunity with Toll-like receptors. Seminars in Immunology. 2009 Aug;21(4):185–193.
<https://doi.org/10.1016/j.smim.2009.05.005>
<PubMed>
32. MN, Spachidou MP, Maratheftis CI. Salivary epithelial cells from Sjogren’s syndrome patients are highly sensitive to anoikis induced by TLR-3 ligation. J Autoimmun. 2010 Nov;35(3):212–8.
<https://doi.org/10.1016/j.jaut.2010.06.010>
33. Mariette X, Gottenberg J-E. Pathogenesis of Sjogren’s syndrome and therapeutic consequences. September 2010 Sept;22(5)471–477.
34. X, Agbalika F, Zucker-Franklin D, et al. Detection of the tax gene of HTVL-I in labial salivary glands from patients with Sjőgren’s syndrome and other diseases of the oral cavity. Clin Exp Rheumatol 2000;18:341–7.
35. A. Toll-like receptors in systemic autoimmune disease. Nature Rev Immunol 2006. 6: 823–35.
<https://doi.org/10.1038/nri1957>
<PubMed>
36. A, Rawlings DJ. B cell autonomous TLR signalling and autoimmunity. Autoimmun Rev. 2008 Feb;7(4):313–6.
<https://doi.org/10.1016/j.autrev.2007.11.027>
<PubMed>
37. NP, Illei GG. Pathogenesis of Sjőgren‘s syndrome. Curr Opin Rheumatol. 2009 Sept;21(5):465–470.
<https://doi.org/10.1097/BOR.0b013e32832eba21>
<PubMed>
38. H, Sasai M, Shida K, Fujita T, Matsumoto M, Seya T. TIR-containing adapter molecule (TICAM)-2, a bridging adapter recruiting to toll-like receptor 4 TICAM-1 that induces interferon-beta. J Biol Chem. 2003 Dec 12;278(50): 49751–62.
<https://doi.org/10.1074/jbc.M305820200>
39. A, Barnard J, Zheng B, et al. Novel human transitional B cell populations revealed by B cell depletion therapy. J Immunol. 2009 May 15;182(10): 5982–93.
<https://doi.org/10.4049/jimmunol.0801859>
<PubMed>
40. D, Anaya JM, Combe B, et. al. Non-Hodgkin’s lymphoma associated with primary Sjögren’s syndrome. Eur J Med. 1992 Oct;1(6):337–42.
41. M, Scott C, Fabris C et al. Mild sialoadenitis: a common finding in patients with hepatitis C virus infection. Scand J Gastroenterol 1994 Oct;29(10):940–2.
<https://doi.org/10.3109/00365529409094867>
42. M, Mu, Zern PB. Hepatitis C virus and Sjögren’s syndrome: trigger or mimic? Rheum Dis Clin North Am. 2008 Nov;34(4):869–84, vii.
<https://doi.org/10.1016/j.rdc.2008.08.007>
43. JD, Arnett FC. The immunogenetics of Sjogren’s syndrome. Rheum Dis Clin North Am. Aug 1992;18(3):539–50.
44. CR, Lanzavecchia A. Toll-like receptor stimulation as a third signal required for activation of human naive B cells. Eur J Immunol. 2006 Apr;36(4): 810–6.
<https://doi.org/10.1002/eji.200535744>
45. I, Anolik JH, Looney RJ. B cell depletion therapy in autoimmune diseases. Front Biosci 2007;12:2546–2567.
<https://doi.org/10.2741/2254>
46. MJ. Activating systemic autoimmunity: B’s, T’s, and tolls. Curr Opin Immunol 2009 Dec;21(6):626–33.
<https://doi.org/10.1016/j.coi.2009.08.005>
<PubMed>
47. SD, Doels P, Van Vooren JP, Cogan E, Appelboom T. Zidovudin in primary Sjőgren’s syndrome. Rheumatology 1999;38:814–7.
<https://doi.org/10.1093/rheumatology/38.9.814>
48. K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol. 2003; 21:335–76.
<https://doi.org/10.1146/annurev.immunol.21.120601.141126>
49. K, Akira S. Toll-like receptors in innate immunity. Int. Immunol 2005; 17:1–14.
<https://doi.org/10.1093/intimm/dxh186>
50. O, Kawai T, Mühlradt PF, et al. Discrimination of bacterial lipoproteins by Toll-like receptor 6. Int. Immunol. 2001 Jul;13(7):933–40.
<https://doi.org/10.1093/intimm/13.7.933>
51. O, Sato S, Horiuchi T, et al. Cutting edge: role of TLR1 in mediating immune response to microbial lipoproteins. J. Immunol. 2002 Jul 1;169(1):10–4.
<https://doi.org/10.4049/jimmunol.169.1.10>
52. O, Takeda K, Hoshino K, Adachi O, Ogawa T, Akira, S. Cellular responses to bacterial cell wall components are mediated through MyD88-dependent signaling cascades. Int. Immunol 2000 Jan;12(1):113–7.
<https://doi.org/10.1093/intimm/12.1.113>
53. GA, Lau CM, Hanley TM, Miko BA, Shlomchik MJ, Marshak-Rothstein A. Activation of autoreactive B cells by CpG dsDNA. Immunity 2003 Dec; 19(6):837–47.
<https://doi.org/10.1016/S1074-7613(03)00323-6>
54. GA, Lau CM, Hanley TM, Miko BA, Shlomchik MJ, Marshak-Rothstein A. Activation of autoreactive B cells by CpG dsDNA. Immunity 2003;19(6): 837–847.
<https://doi.org/10.1016/S1074-7613(03)00323-6>
55. C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjőgren‘s syndrome: a revised version of the European criteria proposed by the American- European Consensus Group. Ann Rheum Dis 2002;61:554–8.
<https://doi.org/10.1136/ard.61.6.554>
<PubMed>
56. M, Sato S, Hemmi H, et al. Essential role of TIRAP/Mal for activation of the signaling cascade shared by TLR2 and TLR4. Nature 2002;420: 324–329.
<https://doi.org/10.1038/nature01182>
57. M, Sato S, Hemmi H, et al. Essential role of TIRAP/Mal for activation of the signaling cascade shared by TLR2 and TLR4. Nature 2002; 420:324–329.
<https://doi.org/10.1038/nature01182>
58. L, Zhang Z, Yu C, Yang C. Expression of Toll-like receptors 7, 8, and 9 in primary Sjögren’s syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010 Jun;109(6):844–50.
<https://doi.org/10.1016/j.tripleo.2010.01.006>
59. L, Yu C, Zhang Z, Yang C, Cai X. Expression of interferon regulatory factor 1, 3, and 7 in primary Sjögren syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009 May;107(5):661–8.
<https://doi.org/10.1016/j.tripleo.2009.01.039>


